These findings, together with its additional involvement in cell migration [96, 97] make DYRK1B an attractive future drug target for many cancer entities, especially for those with a genomic DYRK1B amplicon as encountered in PDAC and ovarian cancer. Here, DYRK1B is linked to ovarian cancer.